Race and Sex Differences in Virologic Response: the HEAT Study
{"Image DocumentName": "Race and Sex Differences in Virologic Response: the HEAT Study", "Image ImageDescription": "Proportion of Subjects with HIV-1 RNA <50 copies/mL at Week 96. Percentage. Analysis of response by sex and by race in the HEAT study found that blacks and women had reduced treatment response rates (defined as viral load <50 copies/mL) compared with the overall and subgroup populations through week 96. African-American race, but not female sex, was a significant predictor of virologic failure using a multivariate logistic regression model. The analysis included 688 patients receiving either abacavir/lamivudine (ABC/3TC) + lopinavir/ritonavir (LPV/r) or tenofovir/emtricitabine (TDF/FTC) + LPV/r: 82% male, 35% black, and 20% Hispanic. No formal assessment of medication compliance was performed. Reference: Smith KY, Kumar PN, Patel P, et al. Differences in virologic response among African-Americans and females regardless of therapy in the HEAT study. 5th IAS; July 19-22, 2009; Cape Town, South Africa. Abstract MOPEB033. 3TC, lamivudine; ABC, abacavir; FTC, emtricitabine; HEAT, Head-to-head Epzicom\u00ae and Truvada\u00ae trial; LPV/r, lopinavir/ritonavir; TDF, tenofovir. Smith KY, et al. 5th IAS. Cape Town, South Africa; July 19-22, Abstract MOPEB033.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}